How many clinical trials are studying RMC-6236?

5 recruiting trials in our tracked data involve RMC-6236.

What conditions is RMC-6236 being studied for?

In our tracked recruiting trials, RMC-6236 is being studied in trials for Lung Cancer, Pancreatic cancer, Non-Small Cell Lung Cancer, NSCLC.

Recruiting trials

Conditions studied

US states with sites

Countries

Phase 1 5 Phase 2 4

Condition	Trials
Lung Cancer · RMC-6236 for Lung Cancer	4
Pancreatic cancer · RMC-6236 for Pancreatic cancer	4
Non-Small Cell Lung Cancer, NSCLC · RMC-6236 for Non-Small Cell Lung Cancer, NSCLC	3
Advanced Solid Tumors	2
Colorectal Cancer	2
Colorectal Cancer (CRC)	2
PDAC	2
Pancreatic Ductal Adenocarcinoma (PDAC)	2
CRC	1
Gastrointestinal Cancer	1
KRAS G12C-mutated Solid Tumors, Lung Cancer	1
KRAS, NRAS, HRAS-mutated NSCLC	1
Lung Cancer Stage IV, Advanced Solid Tumor, Cancer	1
MTAP Deletion	1
Melanoma	1

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 93 locations
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 64 locations
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations